A study has been conducted by a team of Russian scientists including representatives of the City Clinical Hospital No. 67 named after L.A. Vorokhobov and the Gamaleya National Research Center of Epidemiology and Microbiology.
Results obtained show Sputnik V’s efficacy against hospitalisation caused by Omicron for those vaccinated with 3 or 4 components (re-vaccination with Sputnik Light or Sputnik V after Sputnik V) was 97% and 99.4% against critical cases.
For patients vaccinated with at least one component the vaccine’s efficacy was 85.9%.
The study involved over 1,000 patients observed in Moscow.
Sputnik Light is a universal booster to other vaccines thanks to the optimal configuration of Sputnik vaccine’s adenoviral platform which provides better protection against Omicron and other mutations as demonstrated in multiple studies.
Sputnik V has been authorized in 71 countries with a total population of over 4 billion people, and Sputnik Light in more than 30 countries. The Russian Direct Investment Fund invested in development and production of both Sputnik V and Sputnik Light.
Sputnik V and Sputnik Light have been developed using a safe technology that has been widely studied for over 30 years and have not been associated with rare serious side effects such as myocarditis or pericarditis. The highest safety and efficacy of Sputnik V and Sputnik Light was demonstrated in more than 30 studies and real-world data publications from more than 10 countries.
Sputnik V and Sputnik Light can be stored in a conventional refrigerator at +2 +8ºC for 6 months, making them available globally, including in remote territories, without any need to invest in additional cold-chain infrastructure.
Moscow, June 15, 2022 – The Gamaleya National Research Center of Epidemiology and Microbiology (Gamaleya Center) today announced that Vaccines, the leading peer-reviewed medical journal, has published the results of a joint study conducted by team of scientists including representatives of Moscow’s City Clinical Hospital No. 67 named after L.A. Vorokhobov and the Gamaleya Center showing the two-dose Sputnik V registered vaccine COVID 19 RDIF is 97% effective against hospitalisation caused by the Omicron variant of coronavirus (B.1.1.529) among those vaccinated with 3 or 4 components (re-vaccination with Sputnik Light or Sputnik V after Sputnik V).
The corresponding article has been peer-reviewed and is available at:
https://www.mdpi.com/2076-393X/10/6/938/htm
The study was conducted from 11 January to 21 February 2022 involving over 1,000 patients in Moscow. Sputnik V showed high efficacy against hospitalisation at 85.9% among patients vaccinated with at least one component. Efficacy among those vaccinated with 3 or 4 components (re-vaccination with Sputnik Light or Sputnik V after Sputnik V) rose to:
o 97% against any cases of hospitalisation;
o 97.7% against moderate-severe and more severe cases;
o 98.6% against severe and critical cases;
o 99.4% against critical cases.
As authors note, “the study shows that vaccination with Sputnik V and Sputnik Light has a high effectiveness for protection against hospitalisation. The reduction in the severity of COVID-19 regarding the Omicron variant was also observed. The greatest effectiveness was evident in protection against a critical course of the disease requiring patients to be admitted to the intensive care unit.”
To date, Sputnik V vaccine COVID 19 has been authorized in 71 countries with a total population of over 4 billion people, and Sputnik Light has been approved in more than 30 countries. The Russian Direct Investment Fund invested in development and production of both Sputnik V and Sputnik Light.
Message has been successfully sent!
